文献速递消化道肿瘤放疗放疗物理与技术

基线淋巴细胞计数优于剂量学与炎症标志物预测直肠癌严重放射性淋巴细胞减少

Baseline Lymphocyte Count Outperforms Dosimetry and Inflammatory Markers for Predicting Severe Radiation-Induced Lymphopenia in Rectal Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-08-30

本研究纳入179例接受根治性长程氟嘧啶类放化疗的直肠癌患者,评估基线及治疗计划因素对严重放射性淋巴细胞减少的预测能力。结果显示基线绝对淋巴细胞计数(ALC)是主要预测因子,基线四分位间发生率梯度达4倍(Q1 67%至Q4 17%),含ALC、年龄、性别的三变量列线图校正C-index为0.746。第14天ALC更新可提升预测性能,但严重淋巴细胞减少与病理完全缓解、肿瘤退缩或T降期无关。

要点

  • 基线ALC是严重淋巴细胞减少的主要预测因子,四分位间风险梯度达4倍。
  • 女性性别独立增加风险(校正OR 3.44,95%CI 1.69-7.27)。
  • 第14天ALC更新将交叉验证AUC从0.737提升至0.827。

核心结论

  • 常规基线ALC经第14天节点细化后,在严重淋巴细胞减少风险评估中优于剂量学和炎症标志物分析。
  • 列线图似乎识别的是毒性易感性而非治疗效果,支持预期性监测而非修改治疗。

研究设计与样本

  • 研究纳入179例2018至2024年接受根治性长程氟嘧啶类放化疗的直肠癌患者。
  • 基线模型比较基线ALC、年龄、性别、23项全血细胞计数参数、6项炎症标志物和600项剂量学变量,并评估第14天ALC更新。

主要发现

  • 可评估患者中44%发生严重淋巴细胞减少(最低ALC <0.5×10^9/L)。
  • 基线ALC四分位间发生率从Q1的67%降至Q4的17%,呈4倍梯度。
  • 含ALC、年龄、性别的三变量列线图校正C-index为0.746。
  • 女性性别独立增加风险(校正OR 3.44,95%CI 1.69-7.27)。
  • ALC下降71%至第33天最低点,仅19%患者在3个月时恢复至至少1.0×10^9/L。

关键数值与推荐

  • 严重淋巴细胞减少定义为最低ALC <0.5×10^9/L。
  • 已发表的骨盆骨髓V10和Dmean约束分别在98%和100%患者中达标,V20依从率为86%。
  • 严重淋巴细胞减少与病理完全缓解、肿瘤退缩或T降期均无关(所有P > .20)。
  • 基于最低点的未校正生存关联(HR 0.22)在时间依赖校正后消失(HR 0.93)。

临床怎么用

  • 可采用常规基线ALC评估严重淋巴细胞减少风险,并在第14天复查ALC以细化风险分层。
  • 列线图可用于识别毒性易感患者,支持预期性监测而非修改治疗方案。

局限性

  • 骨盆骨髓V10和Dmean约束在大多数患者中已达标,限制了剂量约束的区分能力。
  • 严重淋巴细胞减少与病理完全缓解、肿瘤退缩或T降期无关,提示其反映毒性易感性而非疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine which baseline and treatment-planning factors best predict severe radiation-induced lymphopenia during rectal cancer chemoradiation and whether an early on-treatment absolute lymphocyte count (ALC) measurement refines risk. METHODS AND MATERIALS: We studied 179 patients with rectal cancer treated with curative-intent long-course fluoropyrimidine-based chemoradiation from 2018 to 2024. Baseline models compared baseline ALC, age, sex, 23 complete blood count parameters, 6 inflammatory markers, and 600 dosimetric variables; a day-14 ALC update was also evaluated. RESULTS: Severe lymphopenia (nadir ALC <0.5 × 109/L) occurred in 44% of evaluable patients. Baseline ALC was the dominant predictor; risk showed a 4-fold incidence gradient across baseline quartiles, from 67% in Q1 to 17% in Q4, and a 3-variable nomogram using ALC, age, and sex achieved a corrected C-index of 0.746. Female sex independently increased risk (adjusted odds ratio, 3.44; 95% CI, 1.69-7.27). No platelet index, erythrocyte parameter, inflammatory marker, or dosimetric variable improved prediction; published pelvic bone marrow V10 and Dmean constraints were met in 98% and 100% of patients, respectively, whereas V20 compliance was 86%, limiting dose-constraint discrimination in these standardized fields. ALC fell 71% to a nadir at day 33, and only 19% of patients recovered to at least 1.0 x109/L by 3 months. Week-2 ALC improved cross-validated area under the curve from 0.737 to 0.827. Severe lymphopenia was not associated with pathologic complete response, tumor regression, or T-downstaging (all P > .20). An unadjusted nadir-based survival association (hazard ratio, 0.22) disappeared after time-dependent correction (hazard ratio, 0.93). CONCLUSIONS: A routine baseline ALC, refined by a day-14 checkpoint, outperformed dosimetric and inflammatory profiling for severe lymphopenia risk assessment. The nomogram appears to identify toxicity susceptibility rather than treatment efficacy and supports anticipatory monitoring rather than treatment modification.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Stawiski K, Nowicka Z, Burzyński J, et al. Baseline Lymphocyte Count Outperforms Dosimetry and Inflammatory Markers for Predicting Severe Radiation-Induced Lymphopenia in Rectal Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42669333. doi:10.1016/j.ijrobp.2026.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。